In vitro reactivating effects of standard and newly developed oximes on malaoxon-inhibited mouse brain acetylcholinesterase.

Basic Clin Pharmacol Toxicol

Departamento de Bioquímica, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, Santa Catarina, Brazil.

Published: September 2010

AI Article Synopsis

  • Malathion, an organophosphate pesticide, becomes toxic through its metabolite malaoxon, which inhibits the enzyme acetylcholinesterase (AChE) in humans.
  • Previous treatment efforts with pralidoxime have shown limited effectiveness in reversing this inhibition, raising questions about its routine use in malathion poisoning cases.
  • In this study, newer oximes like obidoxime, trimedoxime, K074, and K075 showed significantly better reactivation of malaoxon-inhibited AChE compared to pralidoxime, suggesting potential new treatment options for malathion poisoning.

Article Abstract

Malathion is an organophosphate (OP) pesticide whose toxicity depends on its bioactivation to malaoxon. Human malathion poisoning has been treated with oximes (mainly pralidoxime) in an attempt to reactivate OP-inhibited acetylcholinesterase (AChE). However, pralidoxime has shown unsatisfactory therapeutic effects in malathion poisoning and its routine use has been questioned. In this study, we evaluated the in vitro potency of standards and newly developed oximes in reactivating malaoxon-inhibited AChE derived from mouse brain supernatants. Malaoxon displayed a concentration-dependent inhibitory effect on mouse brain AChE (IC(50) = 2.36 microM), and pralidoxime caused a modest reactivating effect (30% of reactivation at 600 microM). Obidoxime and trimedoxime, as well as K047 and K075, displayed higher reactivating effects (from 55% to 70% of reactivation at 600 muM) when compared with pralidoxime. The results show that obidoxime, trimedoxime, K074 and K075 present higher reactivating effects on malaoxon-inhibited AChE under in vitro conditions when compared with pralidoxime. Taking into account the unsatisfactory effects of pralidoxime as antidotal treatment in malathion poisonings, the present results suggest that obidoxime, trimedoxime, K074 and K075 might be interesting therapeutic strategies to reactivate malaoxon-inhibited AChE in malathion poisonings.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1742-7843.2010.00576.xDOI Listing

Publication Analysis

Top Keywords

reactivating effects
12
mouse brain
12
malaoxon-inhibited ache
12
obidoxime trimedoxime
12
newly developed
8
developed oximes
8
malathion poisoning
8
reactivation 600
8
higher reactivating
8
compared pralidoxime
8

Similar Publications

The tumor microenvironment in glioblastoma (GBM) is characterized by a pronounced immunosuppressive state, which significantly hampers tumor treatment and contributes to treatment resistance. While our previous research established that black phosphorus nanosheets (BPNS) inhibited glioblastoma cell migration and invasion, the impact of BPNS on the anti-tumor-associated immune mechanism remains unexplored. This study firstly investigated whether BPNS could modulate the tumor microenvironment through immunotherapy and elucidated the underlying mechanisms.

View Article and Find Full Text PDF
Article Synopsis
  • The pathogenesis of long COVID (LC) involves uncertainty, complicating the search for effective therapies.
  • The hypothesis suggests that chronic damage to the body's anti-inflammatory mechanisms, particularly through the vagus nerve, HPA axis, and mitochondrial function, plays a crucial role in LC development.
  • The theory posits that SARS-CoV-2 alters these systems at various levels, leading to persistent inflammation due to impaired anti-inflammatory responses from acetylcholine and cortisol, warranting further investigation into glucocorticoid receptor sensitivity and potential long-term epigenetic effects.
View Article and Find Full Text PDF

Novel PD-L1/VISTA Dual Inhibitor as Potential Immunotherapy Agents.

J Med Chem

December 2024

State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.

Inhibiting the activity of immune checkpoint proteins to reignite the antitumor activity of immune cells has emerged as a pivotal strategy. PD-L1 and VISTA, as critical proteins governing immune regulation, are concurrently upregulated under conditions such as hypoxia. Through a rational drug design process, , a dual-target inhibitor for PD-L1 and VISTA is identified.

View Article and Find Full Text PDF

Hypomethylating agents (HMAs) such as azacytidine and decitabine are FDA-approved chemotherapy drugs for hematologic malignancy. By inhibiting DNA methyltransferases, HMAs reactivate tumor suppressor genes (TSGs) and endogenous double-stranded RNAs (dsRNAs) that limit tumor growth and trigger apoptosis via viral mimicry. Yet, HMAs show limited effects in many solid tumors despite the strong induction of TSGs and dsRNAs.

View Article and Find Full Text PDF

This study evaluates the clinical impact of comprehensive nursing care on senior patients suffering from postherpetic neuralgia (PHN), a chronic neuropathic pain condition resulting from the reactivation of the varicella-zoster virus. A total of 102 elderly patients diagnosed with PHN and treated at our hospital were divided into two groups: the control group, which received conventional nursing care, and the intervention group, which received comprehensive nursing care. Comparative analyses were conducted on pain levels, sleep quality, symptoms of depression and anxiety before and after the intervention.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!